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Abstract: Tuberculosis (TB) is the primary cause of death by a single infectious agent; responsible
for around two million deaths in 2016. A major virulence factor of TB is the ability to enter a
latent or Non-Replicating Persistent (NRP) state which is presumed untreatable. Approximately
1.7 billion people are latently infected with TB and on reactivation many of these infections are drug
resistant. As the current treatment is ineffective and diagnosis remains poor, millions of people
have the potential to reactivate into active TB disease. The immune system seeks to control the
TB infection by containing the bacteria in a granuloma, where it is exposed to stressful anaerobic
and nutrient deprived conditions. It is thought to be these environmental conditions that trigger
the NRP state. A number of in vitro models have been developed that mimic conditions within
the granuloma to a lesser or greater extent. These different models have all been utilised for the
research of different characteristics of NRP Mycobacterium tuberculosis, however their disparity in
approach and physiological relevance often results in inconsistencies and a lack of consensus between
studies. This review provides a summation of the different NRP models and a critical analysis of
their respective advantages and disadvantages relating to their physiological relevance.
Keywords: tuberculosis; latency; non-replicating persistent; antibiotic; drug discovery;
Mycobacterium tuberculosis
1. Introduction
Tuberculosis (TB) is the ninth leading cause of death in the world and is the primary cause
of mortality by a single infectious agent [1]. According to the World Health Organisation (WHO)
there are more than 10 million new cases of TB recorded every year; particular hotspots for TB
incidence include Sub-Saharan Africa and South-East Asia. There were an estimated 1.7 million
fatalities caused by TB in 2016 of which 375,000 were in HIV-positive people who bear a heavy
burden of TB disease, however the global TB mortality rate is falling at 3% a year [1]. The causative
agent of TB, Mycobacterium tuberculosis, is spread by aerosolisation when infected individuals cough.
The exhaled droplet nuclei carry M. tuberculosis which is then inhaled by a nearby individual [2].
The infectious dose for M. tuberculosis infection is around 1–5 bacilli [3]. M. tuberculosis progresses to
the lungs, where they largely inhabit the resident professional phagocytes. As the disease progresses,
neutrophils, monocytes, and eventually dendritic cells are recruited by distress signals from the
infected macrophages [4,5]. These innate immune cells are then infected as well, compounding the
problem. When the adaptive immune system takes control, the bacteria mainly arrest their growth
and symptoms become transient or non-existent [6]. In immunocompetent individuals, the adaptive
immune system is able to contain M. tuberculosis infection by sealing the bacteria in a cooperative
group of cells from the innate and adaptive immune system that isolate the bacteria from the rest
of the body [7–9]. At this point, progression to latent disease occurs in up to 90% of individuals.
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If the granuloma cannot be maintained due to immune impairment, M. tuberculosis is released and the
infection progresses to active TB disease. At this point the individual becomes infectious and starts to
shed bacteria [10]. They also become symptomatic: general symptoms of TB include fatigue, weight
loss, and coughing up bloody sputum [11]. Growing incidences of drug resistance, a high burden of
disease and increasing socio-economic determinants such as war and high levels of poverty indicate
that more action is needed to eradicate this expanding public health problem [12–15].
To achieve the WHO “End TB Strategy” objective of a 90% reduction in TB by 2035, a unified
strategy which improves diagnosis and treatment of both latent and active TB is crucial [14,16].
Latent TB, otherwise known as Non-Replicating Persistent (NRP) TB [17], is one of the main
mechanisms of TB virulence. It can survive in the host for decades without becoming symptomatic and
will only reactivate when the host becomes immunocompromised, even to a small degree [10,18,19].
Latent TB is not a faithful term for the changes that M. tuberculosis undergoes. The term “latent”
often refers to a dormant state with no active metabolic processes and no response to environmental
stimulus. This is not true in the case of TB: its metabolism is regulated to an essential level but is still
functional [20–22]. The phrase Non-Replicating Persistence (NRP) was first used by Wayne in 1976
and has since become adopted as the appropriate term to describe this state [17,23].
Latent TB is diagnosed by a positive Tuberculin Skin Test (TST)—which produces an antigen
(tuberculin) specific T cell response—without the presence of symptoms [24,25]. By mathematical
modelling, it has been estimated that 1.7 billion people are latently infected with TB [26]. Of these,
around 56 million are deemed highly likely to reactivate into active disease [26]. It is highly likely
that a large proportion of the latent disease is drug-resistant and so could reactivate into MDR
TB [19]. Both forms of the disease are exceptionally hard to treat and even with intensive combination
therapies, treatment is only 54% successful [1]. The lack of effective treatment options for MDR TB is a
problem that will only increase with the spread of antibiotic resistance [27]. Therefore, a treatment that
effectively targets the asymptomatic, latent state of TB is preferable to current therapies; this would
also help to eradicate the currently daunting reservoir of active infection as 90% of all infections are
latent [1,14,18].
When M. tuberculosis is contained by the adaptive immune system within the TB granuloma [28],
a distinct metabolic and physiological shift takes place [21,29]. The genes expressed are distinctly
different to the active phenotype [29]. This genetic shift is now thought to be caused or largely
influenced by the metabolism of cholesterol [21], instead of other preferable fatty acids (glycerol) or
glucose [20]. Cholesterol is known to be the only carbon source present in the granuloma as, over time,
all other carbon sources have been used by the bacteria whilst still active [20,30].
Treatment of TB is preferable when the disease is in the NRP state and the patient is not expressing
any symptoms. To do this, novel compounds require screening against an in vitro model of NRP
TB. There have been a few different models of NRP TB developed all with unique advantages and
disadvantages. These different models can all be utilised for the research of different physiological
characteristics of the NRP state. This review provides a summation of the different NRP models and a
critical analysis of their respective advantages and disadvantages.
2. Conditions within the Granuloma
Conditions found within the granuloma are key to the NRP state and accurately mimicking these
conditions in vitro allows for the development of new models. The environment in the granuloma
has a distinct profile that includes hypoxia [17,23], nutrient deprivation [31–33], limited carbon
sources [21,22,33], and a high concentration of nitric oxide (NO) [34]. Most of the above environmental
conditions have been shown to induce the NRP state in mycobacteria individually. It could be
presumed that the combination of all these conditions will produce a phenotype closest to that found
clinically. Nevertheless, most in vitro models focus on one of the conditions in isolation—although
there are a few that combine two conditions in their model. A summary of the models discussed can
be found in Figure 1.
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3.1. The ayne odel
In 1976, Lawrence Wayne made the observation that whilst an M. tuberculosis culture was aerated,
growth would continue in a logarithmic fashion; if aeration was stopped, the culture settled and
the concentration of dissolved O2 (dO ) decreases, growth ould arrest seemingly indefinitely [23].
The concentration of dO2 was increased by shaking, which lead to the continuation of exponential
growth after an extended period of time in an arrested state. This discovery of the effect of an oxygen
gradient on M. tuberculosis was the first indication that M. tuberculosis could enter a state similar to
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latency, but being subtly different. He coined the state Non-Replicating Persistence (NRP) to reflect
the differences [17,35]. After a few improvements, Wayne introduced an in vitro model of Latent TB
based on his observations of the effect of hypoxia. His hypoxic model, termed The Wayne Model,
was introduced in 1996 [35]. The aim of this model was to simulate the gradual depletion of oxygen
in the granuloma. The organisms were grown in sealed containers with a controlled ratio of air
to culture medium equalling 0.5. This ratio is called the Head Space Ratio (HSR). As the culture
grows aerobically, it slowly uses up all the oxygen in the HSR: thus, creating the slow shift down into
anaerobic conditions due to the reduction in dO2. This model contains two distinct states of NRP.
The first occurs just as the oxygen saturation in the HSR reaches 1%. Wayne called this NRP stage
I [17,35]. This stage is described as “microaerophilic”, where the bacilli are no longer replicating or
conducting DNA synthesis but still have high levels of ATP production and some active mechanisms
of DNA repair [17,29,36]. This is followed by NRP stage II, characterised by fully anaerobic conditions
defined as below 0.06% oxygen saturation [35]. NRP stage II is the phenotype most often referred to
when describing NRP M. tuberculosis. It is important to note that M. tuberculosis cannot survive if placed
straight into NRP stage II conditions: the process of steady decrease in oxygen saturation in NRP stage
I is necessary to achieve NRP stage II [35]. Hypoxia is confirmed by the decolourisation of methylene
blue (concentration of 1.5 µg/mL) and by a stabilisation of the growth curve into a plateau [37],
sometimes referred to as an early stationary phase. Under this model, M. tuberculosis is indifferent to
the presence of Isoniazid (INH) but the presence of Metronidazole (MET) has a bactericidal effect [38].
This is directly opposed to the effect of these drugs in aerobic conditions where INH has a bactericidal
effect on M. tuberculosis but MET has no inhibitory effect [39].
This model is the first to model in vitro NRP M. tuberculosis, and is still the model of choice for
most Latent TB researchers. Whilst this model has facilitated a great increase of knowledge into Latent
TB and its metabolic profile, it does have some limitations. Firstly, the bactericidal effect MET has
anaerobically is not reflected in animal models, such as the Cornell mouse model [40] and a guinea pig
model [41]. This has led to the assumption that MET would have no effect if used therapeutically and
has cast doubt on other active compounds identified using the Wayne model.
This is perhaps related to the Wayne model singularly focussing on replicating the slow shift
to hypoxic conditions that happen in the granuloma; it does not include any other environmental
conditions found in granuloma [42] (Figure 1). These other factors have an effect on the physiological
and metabolic profile of the M. tuberculosis which would cause the bacteria to react in a different manner
to challenges. Therefore, as the Wayne model lacks these other physiologically relevant conditions, any
NRP active antimicrobials identified using this model are treated with some speculation. The bacteria
have a different physiological and metabolic profile in vivo and this is reflected in the difference in
drug profiles [41].
Nevertheless, this model is still frequently used in research and has provided large contributions
of knowledge and insight into NRP physiology. In addition, a large majority of recent models borrow
heavily from the Wayne model. Therefore, this primitive starting point has paved the way for a
multitude of other models for NRP in M. tuberculosis.
3.2. Hypoxic Resazurin Reduction Assay (HyRRA)
The following model is an example of an in vitro model that has a focus on high throughput
phenotypic screening (HTPS). With the demand for new antimicrobials ever increasing, HTPS has
become the method of choice for identifying novel active antimicrobials [43]. Whilst HTPS commonly
lacks specificity compared to other testing methods, the ability to quickly and frugally screen high
volumes of novel compounds to identify new inhibitory molecules is both cost and time efficient.
The HyRRA model is based on principles from the Wayne model [35] and an aerobic HTPS
M. tuberculosis assay called Resazurin Microtitre Assay (REMA) [44]. Colorimetric assays such as
REMA or an Alamar blue assay have become as common as rapid, inexpensive methods of visual
minimum inhibitory concentration (MIC) identification [44,45].
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The HyRRA was tested on M. tuberculosis H37Rv, Mycobacterium smegmatis, and Mycobacterium
bovis BCG. All species were cultured in 3 mL aliquots in sealed vacutainer tubes, then kept static to
induce hypoxia. Drugs were then aseptically added, and the dosed cultures were incubated for 96 h.
After this point, the cultures were dispensed into microtitre plates and 0.02% resazurin was added.
Resazurin is reduced to Resorufin in the presence of metabolically active cells, thus causing a colour
change from deep purple to pink [46]. This cell viability assay was then used to screen a large antibiotic
panel using this model, and compare the MICs of these compounds against previous models’ findings
and classic colony forming units (CFU) assay [47]. The MICs identified by the colourimetric assay
were found to be comparable to those found from CFU counts. They found activity against NRP TB
from compounds from the nitrofuran group [48]. In this model, as with the Wayne model, the bacteria
tested show sensitivity to MET, potentially due to the shared hypoxic condition.
This model facilitates the down-scaling of NRP M. tuberculosis drug testing to enable a HTPS,
improving the discovery of new antimicrobials expeditiously. This is a considerable advantage as
previous models struggled to adapt to screening a large quantity of novel compounds. As with the
Wayne model, the HyRRA model is based on the hypoxic environment found inside the granuloma.
The presumption made is that if hypoxia alone can trigger entry to the NRP state, then hypoxia alone
is enough to model the granuloma [17,35]. This is partially correct: hypoxia does trigger entry into
the NRP state and will maintain the bacteria in this state, so it is correct to presume that hypoxia is a
large driving factor of NRP. However, as discussed later in this review, hypoxia is not the only stress
condition present in the granuloma with the ability to trigger the NRP state (Figure 1). The HyRRA
solely focusses on one stress condition that can induce the NRP state in mycobacteria. This induction
facilitates compound testing on mycobacteria in the NRP but without the other conditions, the
compound testing will never be physiologically relevant and as such will produce many false positives.
Additionally, many compounds could take longer than 96 h to depict a sterilising action and so this
method could exclude some potential compounds.
3.3. Low Oxygen Recovery Assay (LORA)
Another model which is more adapted to HTS is the Low Oxygen Recovery Assay (LORA) [49].
Large elements of this model are based on the Wayne model [35] and as such could potentially be
characterised as an adaptation of the Wayne model instead of a standalone model. The LORA assay
makes use of a luciferase reporter (luxAB gene) [50] to depict the metabolic activity level of cells
and the authors showed that, on entrance to the NRP state, luminescence decreased but remained
present and constant as the experiment progressed [49,51]. In short, the recombinant M. tuberculosis
H37Rv was manipulated into NRP stage II using a similar protocol to Wayne’s [35], albeit using a
chemostat to accurately control conditions such as dO2. After 22 days under these conditions with
regular optical density readings (OD570nm), CFU counts, and Relative Light Unit (RLU) readings taken,
the cultures were spun down in Phosphate-Buffered Saline (PBS) and frozen at −80 ◦C. These stocks
were challenged with antimicrobial agents for 10 days under anaerobic conditions and then given a
day’s aerobic recovery. Again, luminescence and CFU counts were taken.
To determine the suitability of this assay’s use as a HTPS, a Z’ test was conducted [52]. The LORA’s
Z’ factor was determined from the RLUs after 10 days of anaerobic incubation and was determined to
be in the range of 0.58–0.84. A Z-factor value between 0.5 and 1 is indicative of an excellent assay that
is suitable for HTS, therefore the LORA is suitable as a HTPS [52].
The authors tested 31 antimicrobial compounds using this model and compared this to a
comparative aerobic counterpart and previously recorded results. As found in the Wayne model,
INH, which targets the cell wall [53], has no effect on NRP M. tuberculosis [17,39]. This lack of efficacy
is also consistent clinically. Other drugs that have cell wall targets were also found to be inactive
such as Ethambutol and Cycloserine [49]. In agreement with previous models finding: MET [38],
Capreomycin [54], and Moxifloxacin [55] had strong sterilising activity among some other active
compounds. The general conclusion drawn is that cell wall targeting drugs become inactive in NRP.
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However, those drugs with intracellular targets such as MET and compounds, including Capreomycin
that target the 30S ribosomal subunit, gain activity [38,54].
An example of the LORA being used to identified novel compounds was shown by Bonnett et al.
where they identify hydrazones as active against NRP M. tuberculosis [56]. These hydrazones were
previously identified as effective compounds against active TB. The drug target was found to be the
enzyme LepB which is a crucial part of the general secretion pathway of TB [57].
The LORA model has many advantages as a model and as previously discussed, the world of drug
discovery has an ever increasing focus on HTPS [43]. The LORA’s suitability for HTPS as confirmed
by the Z’ [52] is encouraging; as the authors showed, a wide variety of compounds can be screened
with comparative ease when compared to the Wayne Model [35,38]. The use of a luciferase reporter
to monitor entry to the NRP state as well as drug activity is novel. This provides a wider range of
information than what could be gleaned from previous models such as the HyRRA which uses a
qualitative measure to determine the culture entry to NRP [47,49].
Nevertheless, as with all models, there are some disadvantages to using this in vitro model.
Similar to the HyRRA and the Wayne model, this model is based exclusively on hypoxia [35,47,58].
As previously discussed, this is an important element but is not independent clinically (Figure 1).
Secondly, this is a model based on determining the MIC of novel compounds whose activity
and target may not have been identified. The luciferase reporter enabled assessment of the metabolic
activity observed in the NRP state. However, to transform the M. tuberculosis, a kanamycin selective
marker was used [59]. This means that the recombinant M. tuberculosis H37Rv-luxAB is resistant to
kanamycin. This has the potential to confer some level of resistance to other antimicrobials. This is
especially relevant when conducting a HTPS on novel compounds. This could lead to the elimination
of some compounds that clinically could have powerful sterilising activity.
Finally, this assay requires special instruments (Anoxomat system) and is expensive to run with
a high cost of reagents and equipment. Generally, the optimal HTPS should be as inexpensive as
possible because of the potential low yield of active compounds [43].
3.4. Red Fluorescent Protein (RFP) Model
This model is also a HTPS of NRP M. tuberculosis that is based on the hypoxic element of the
granuloma [60]. This model exposed the disadvantage of previous hypoxic models [35,49] which was
to maintain hypoxia, all elements of the experiment (both culture and compound) are added together
and sealed or placed in an anaerobic cabinet. However, entry to the NRP state takes a period of time
extending from 48 h to 120 h dependent on conditions [23,31,35]. For approximately the first 72 h
in previous models, the M. tuberculosis was still in its active state. Therefore, as some compounds
(for example rifampicin) are very fast acting compounds; activity to NRP M. tuberculosis could be
shown. In fact, the compound would have been faster to sterilise the culture than the M. tuberculosis
was to turn NRP. The Red Fluorescent Protein (RFP) model aims to overcome this hurdle by combining
molecular biology techniques and a different method of excluding oxygen.
Red fluorescent protein can be utilised as a reporter for gene expression and so can be used to
determine the difference between an actively growing culture, a static culture and a culture affected by
a bactericidal drug [61]. RFP protein was transformed into M. tuberculosis H37Rv using the pCHERRY3
plasmid [62].
This model also made use of microtitre plates to conduct a HTPS. Cultures were grown aerobically
and then a layer of paraffin oil was added on top of the culture which oxygen cannot permeate [63].
To test if the culture is hypoxic, methylene blue was added (1.5 µg/mL), which decolourises in the
absence of oxygen [35]. This was incubated for 13 days, at which point compounds were injected into
the hypoxic cultures through the paraffin oil layer. This was then incubated for a further 20 days with
daily fluorescence readings taken [60].
A wide range of compounds were tested, each chosen for their differing modes of action [60].
A notable feature of all the previous hypoxia models is sensitivity to MET [35,47,49]. Interestingly, the
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RFP model does not show any sensitivity to MET. The authors postulate that this discrepancy could be
due to MET being a pro-drug and its activation is largely based on the state of the bacilli [60]. However,
this sensitivity to MET is not seen in any in vivo test, therefore, this lack of sensitivity could indicate an
improved physiological advantage to the model [41]. This model also highlighted the extended period
of time needed for some compounds to show activity such as the aminoglycosides. Some previous
models did not expose the cultures to the compounds for this extended period of time. The drug
resistant nature of the bacilli can require a large lead time before the compounds take effect [64].
As in the previous tests, a Z’ analysis was conducted to see whether this model is suitable for a
HTPS [52] which gave a value between 0.91–0.94, indicating that this model is robust for HTPS.
The main advantages of this model have already been touched upon. Briefly, other models
previously exposed cultures to compounds before they had gone fully into the NRP state [31,35,47,65].
This model ensures that compounds are only tested against Mycobacterium that have fully entered the
NRP state. Secondly, this model shows that the bacteria are demonstrably in the NRP state, however,
there is no susceptibility to MET. Therefore, it could be postulated that hits generated using this model
are more physiologically relevant than those identified by previous models. Finally, this model exposes
the NRP cultures to compounds for an extended period of time compared with previous models.
Some compounds take a long time to act on this highly resistant phenotype of M. tuberculosis; so a
shorter period of time could exclude some compounds that have a high efficacy but need longer to
take effect.
Introduced in 2018, this model represents the most recent offering towards NRP research and
addresses some of the issues with previous models. Nevertheless, no model perfectly simulates the
clinical, in vivo condition and there are disadvantages associated with this model. As with the LORA,
this model utilises a transformed version of M. tuberculosis [49]. This involved the transformation of
M. tuberculosis H37Rv with RFP using the pCHERRY3 plasmid, which uses a hygromycin selective
marker [61]. Using a culture that already has some antimicrobial resistance is not ideal as it could lead
to some level of cross resistance to other antibiotics.
In addition, hypoxia is the only element of the granuloma being imitated in this model, as in
the other models. As the subsequent models will demonstrate, other NRP-inducing conditions have
similar but not identical transcriptomes [66]. To create a model that is physiologically relevant, all
conditions should be taken into account (Figure 1).
4. Nutrient Deprivation and Selective Carbon Sources
As early as 1933 (Figure 2), nutrient deprivation was indicated as able to induce the NRP state in
TB [32,67]. In recent years, this work has been further developed and has shown granuloma-based
bacteria that are not only nutrient starved [31,68], they are restricted to odd chain fatty acids as the
sole carbon source, namely cholesterol [21,22]. The effect of nutrient starvation has been less studied
than hypoxia; however, the following models all show that they can model NRP M. tuberculosis albeit
with a different drug sensitivity profile to that observed in hypoxia-derived NRP mycobacteria.
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Figure 2 presents a representation of the introduction of in vitro models of Non-Replicating
Persistent Tuberculosis in combination with the landmarks of Tuberculosis research. Orange markers
represent milestones in TB discovery and treatment. The blue markers represent the introduction
of the varying models, where LORA indicates the Low Oxygen Recovery Assay and HyRRA is an
abbreviation for the Hypoxic Resazurin Reduction Assay.
4.1. The Nutrient Deprivation Model
In 1933, in vitro TB research was still relatively new; Loebel and his team demonstrated that it is
possible to transfer an M. tuberculosis culture out of rich media into PBS [32], which then can be left in
solution for many years (Figure 2). Respiration levels slowly decreased and the culture remained in
early stationary phase; however, upon reintroduction to rich media, respiration levels increased and
the bacterial cells resumed normal growth [67]. Loebel concluded that it was possible for M. tuberculosis
to survive for an extended period of time and that this virulence factor could be attributed to the
bacteria’s ability to “depress its oxygen consumption and to live off previously stored foodstuffs”.
This postulate was later proved to be correct by subsequent models [17,31].
M. tuberculosis from a granuloma has a different morphology to those grown in vitro, however,
nutrient starved M. tuberculosis has a similar morphology to the in vivo phenotype [33]. This would
suggest that nutrient starvation is an essential environmental condition in the granuloma with an
altered genetic profile that in vivo could work in conjunction with hypoxia activated genes to produce
the clinical phenotype [20,58,69]. Betts and her research team came up with a model based on Loebel’s
earlier work that would stop respiration and halt replication but keep the bacteria viable [31,32,67].
In this model, bacteria are grown for 7 days in nutrient rich media at which point they are
pelleted and resuspended in PBS. They are incubated at 37 ◦C in sealed containers [31]. Viability is
determined by CFU counts at sequential points. Despite no growth at any point, the CFU counts
remained consistent throughout, which indicated that the NRP state had been achieved. Interestingly,
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despite being cultured in a sealed container, similar to the Wayne model, there is no decolourisation of
methylene blue which shows that oxygen is still present in the cultures [31,42].
The Wayne model was used as a control and as previously seen, after 10 days in sealed containers
containing rich media, the culture decolourised methylene blue and entered hypoxia [35].
This led to the hypothesis that, instead of the oxygen being consumed, as in the Wayne model [35],
the bacilli slowed down their respiration levels and thus entered the NRP state. In this model of NRP,
bacteria gain resistance to INH and RIF, however, they do not gain susceptibility to MET [31]. This is
one of the primary differences between the Nutrient Deprivation model and the Wayne model [17,31].
They also noticed a difference in gene expression in response to nutrient starvation. They found many
enzymes concerned with energy metabolism are downregulated under nutrient-deprived conditions.
These enzymes included ones in the tricarboxylic acid (TCA) cycle (fum, acn, icd1) and in glycolysis
(gap, tpi). Sigma factor B (sig) was also found to be upregulated. Expression of sigB has been associated
with the transition into stationary phase and has also been associated with stress conditions [70,71].
An analysis of the whole transcriptome of M. tuberculosis in both models showed many similarities
including an adaptation in metabolism. However, whilst the model shared 50 “top scoring” genes
with the Wayne model, there were over 200 different upregulated genes [66].
This is also a widely accepted model of NRP, made interesting by its different drug susceptibility
to the Wayne model. This difference could be attributed to its distinctly different transcriptome [66].
Nevertheless, entry into the NRP state can be observed despite oxygen being abundant [31]. All the
above evidence seems to imply that both nutrient starvation and hypoxia are essential conditions in
the granuloma to provide the right environment for NRP.
From this, both models have the same failure of only looking at one environmental factor without
reflecting the full picture of physiological conditions within the granuloma (Figure 1).
4.2. Stationary Chemostat Model
Building on this work into investigating the effect of nutrient deprivation on M. tuberculosis, a
new model was proposed which aimed to use a chemostat to tightly control conditions such as pH,
temperature, and dissolved oxygen [31,32,67,72]. This stationary chemostat model would allow the
long-term maintenance of an NRP culture. Chemostats have been utilised by scientists attempting
to culture many different bacteria under challenging conditions as it allows greater control of the
environment than traditional culture methods [73–75].
This model cultured M. tuberculosis H37Rv in 750 mL of ADC enriched Middlebrook 7H9 broth
with a defined dissolved oxygen concentration of 50%. This culture was then maintained until all
the nutrients has been depleted; this slowing of growth was defined as stationary. The depletion
of glucose and glycerol was monitored by biochemical assays over the duration of the experiment.
Culture samples were extracted from the chemostat at intervals throughout the experiment and plated
for CFU counts. To monitor the transcriptome of the culture, RNA was extracted at various time points
throughout the experiment.
The authors have based this model on the theory that there is a proportion of bacteria that
go into an extended stationary phase in response to an external pressure, similar to what is seen
in Escherichia coli [76]. This could be generated in vivo by exposure to antibiotics to which a small
proportion of the population would survive (persister population). They observed what they have
defined as stationary phase up until day 80, which they attribute to nutrient deprivation, at which
point the culture restarts growth. This revival is hypothesised to be the result of adaptation to the new
growth environment.
The main advantage of this model is that it is conducted in a chemostat, which had not previously
been explored as an option for NRP M. tuberculosis. Rigidly controlling the environment to simulate
known conditions in the granuloma is a widely employed method of in vitro modelling.
The theory that the condition of Latent TB is caused by stationary persisters as discussed by this
study requires further validation. This would have merit if the bacteria were solely extracellular and if
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this phenomenon did not occur in individuals who had not received antibiotic chemotherapy for their
TB [10]. An interesting facet of M. tuberculosis infection is the ability to survive extracellularly and
intracellularly [77]. It has long been thought that the primary infection is driven by the extracellular
bacteria; the intracellular bacteria (predominately residing within the macrophages) are the bacteria
involved in the granuloma [17]. Hence, it is the intracellular bacteria that are mainly exposed to the
conditions of the granuloma which are the driving force to the persistence of M. tuberculosis [17,78].
In addition, the culture showed a resuscitation at 80 days; as early as 1933, it was shown that
M. tuberculosis can persist in sealed containers for 12 years [79]. This evidence in addition to patients
reactivating after 20 years provides compelling evidence that this model does not achieve the persistent
sate observed clinically [64].
Another hallmark of persistence of M. tuberculosis is the cessation of replication as observed by
previous models [31,39,79]. The growth curves displayed in this model do not show a stable, persistent
population but a population in a slow decline [72]. This type of growth curve is more reminiscent of a
culture in the decline phase of the growth curve: attributed to the depletion of glucose and glycogen.
It is possible that the culture has not entered the NRP state but instead has progressed into decline
phase, and before this could complete, the bacilli found a new source of nutrients. A large amount of
Tween 80 is used in the medium (0.2%), the stereotypical level of Tween 80 in mycobacteria cultures
is 0.05%. It has been identified that mycobacteria can utilise Tween 80 as a carbon source [80,81].
Therefore, whilst the culture has been deprived of glucose and glycerol—which could contribute to the
culture’s longevity—it cannot truly be described as nutrient deprived as there are alternative carbon
sources present [72]. The original nutrient deprivation model utilised PBS, as have subsequent models,
and have demonstrated long term persistence and viability [31,32].
This model has many promising features, such as the innovative use of a chemostat for NRP
M. tuberculosis culture. However, to be utilised as a strict model of NRP, the media used in this study
may need to be reviewed to reflect the long term persistence seen in other models [31,39].
5. Nitric Oxide
The previous models have highlighted the two best known environmental conditions of the
granuloma: hypoxia and nutrient deprivation [17,31]. Nevertheless, there are other lesser studied
environmental conditions that can induce M. tuberculosis to enter the NRP state, such as the presence
of nitric oxide (NO). Activated macrophages produce NO as a signalling molecule and as a potent
antibacterial chemical [34]. NO has also been associated with the inhibition of mitochondrial and
bacterial respiration [82]. It has also been shown that NO is responsible for the control of mycobacterial
replication, along with various other cytokines and chemokines, such as interferon-γ and tumour
necrosis factor-α [83].
This model investigated whether NO would trigger NRP; as a low, non-toxic concentration inhibits
bacterial respiration. Inhibited respiration could led to the same state as hypoxia, since hypoxia also
limits respiration, but by the depletion of oxygen [84]. M. tuberculosis is cultured in the widely used
Middlebrook 7H9 broth in aerobic conditions but with a subtoxic concentration of NO. The authors
introduced this as less of a structured model of in vitro NRP and more of a study into whether NO can
independently trigger the NRP state.
Exposure of M. tuberculosis to NO was shown to induce a 48-gene regulon via the DosR
regulator [29]. The DosR regulator or the dormancy survival regulator was identified previously using
the Wayne model as being essential for survival in hypoxic conditions [85,86]. DosR is responsible for
activating one of the key NRP genes, acr (M. tuberculosis alpha-crystallin/Rv2031), which has been
shown to be essential for the growth of M. tuberculosis in macrophages [86,87].
NO was also showed to inhibit mycobacterial respiration and halt replication in this model.
Evidence that would suggest that NO is key to NRP state is the activation of key genes that seem to
show that under hypoxic conditions, nitrate becomes the terminal electron acceptor [88].
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The effects of NO on M. tuberculosis induces the same genes and thus physiology as hypoxia does,
albeit via a very different methodology. The induction of the DosR regulon, the cessation of growth
and the inhibition of respiration are all key markers of the NRP state in both hypoxia and nutrient
deprivation [82,89]. The ability of NO to independently produce a similar phenotype to both other
conditions highlights the importance it must have in the clinical phenotype.
This has not yet been developed into a functional model and there have been no drug panels
tested against it. Nevertheless, as it shares such a close phenotype to that of hypoxia, the presumption
is that the drug profile should be, by and large, the same [54]. The discovery that NO can induce the
NRP state in M. tuberculosis is a leap forward in knowledge concerning this physiological state and its
triggers. However, the NO model requires further development before it can be compared with the
other models [31,39].
6. Streptomycin Dependent
Finally, there is a Streptomycin-dependent model which utilises the 18b strain of M. tuberculosis
which has mutated to only grow in the presence of Streptomycin [90]. When this antibiotic is removed,
replication ceases [91]. The theory behind this model is that this cessation of replication due to the
removal of Streptomycin could mimic the NRP state [17,91]. Cultures were grown in Middlebrook 7H9
media in the presence of 50 µg/mL of Streptomycin. The Streptomycin is removed and the cultures
are then starved for two weeks before being exposed to antimicrobial compounds. The protocol for
drug testing is the REMA and it is the same method that the HyRRA is based on [44,47].
This model reports an altered drug profile to those seen in more developed models [91]. A full
drug panel was screened against the model and showed no activity from INH but an increased
susceptibility for front-line antibiotic Rifampicin [91]. Also identified was the strong sterilising action
of new TB compound of interest, PA-824 [92,93]
This model attempts to mimic entry into the NRP state via the removal of streptomycin. However,
the NRP state is still not fully understood: the transcriptome and physiology can vary between different
models that exhibit different granuloma conditions [17,31]. This model was presented as an easy,
affordable, and reliable way of conducting a HTPS on NRP mycobacteria. The altered drug profile
observed when using this model casts doubt on the ability to accurately screen in vitro for effective
drugs in vivo [19,40]. This is coupled with the model not mimicking any part of the granuloma, and as
we do not yet know the implications of these environmental conditions, crucial elements of the NRP
state could be missing from this model.
7. Summary
Despite recent interest, there is still a large void in knowledge concerning the NRP state, both
genetically and physiologically (Figure 2). Many attempts have been made at modelling the NRP
state in vitro, all contributing different approaches and goals. However, there hasn’t yet been a widely
accepted model proposed that mimics more than one aspect of the granuloma. Trying to replicate just
one condition has a lot of merit as it allows a deep investigation into the effects of one variable on
the bacteria. The other argument is that if just one condition in isolation can trigger the NRP state,
combining all the other conditions in one unwieldy model is unnecessary.
However, when modelling a bacterial infection with the purpose of novel drug screening, the
model needs to be as representative of the clinical disease as possible. As the above models show,
the different environments all induce a clearly distinct NRP state with different genetic profiles and
drug susceptibility (Figure 1). The current practice to address this issue is to use several of the models
previously discussed in tandem to screen for new antimicrobials. The consequence of this is that these
environments are not found individually in vivo. In reality, these distinct phenotypes fuse to form a
third phenotype, the clinical phenotype (Figure 1). It is this clinical phenotype that requires future
in vitro modelling if novel drug screening is to be met with any success.
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